Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study
Authors:
- Ioannis PsallidasIPIoannis Psallidas
- Sophia P KarabelaSKSophia P Karabela
- Charalampos MoschosCMCharalampos Moschos
- Taylor P SherrillTSTaylor P Sherrill
- Androniki KollintzaAKAndroniki Kollintza
- Sophia MagkoutaSMSophia Magkouta
- Panagiota TheodoropoulouPTPanagiota Theodoropoulou
- Charis RoussosCRCharis Roussos
- Timothy S BlackwellTBTimothy S Blackwell
- Ioannis KalomenidisIoannis Kalomenidis
- Georgios T StathopoulosGSGeorgios T Stathopoulos
Open Access
- 10 March 2010
- journal article
- Published by Springer Nature in Molecular Cancer
- Vol. 9 (1) , 1-11
Abstract
Background: We have previously shown that nuclear factor (NF)-κ B activation of mouse Lewis lung carcinoma (LLC) specifically promotes the induction of malignant pleural effusions (MPE) by these cells. In the present studies we hypothesized that treatment of immunocompetent mice with bortezomib tailored to inhibit cancer cell NF-κ B activation and not proliferation specifically inhibits MPE formation by LLC cells. Results: Treatment of LLC cells with low concentrations of bortezomib (100 ng/ml) inhibited NF-κ B activation and NF-κ B-dependent transcription, but not cellular proliferation. Bortezomib treatment of immunocompetent C57BL/6 mice bearing LLC-induced subcutaneous tumors and MPEs significantly blocked tumor-specific NF-κ B activation. However, bortezomib treatment did not impair subcutaneous LLC tumor growth, but was effective in limiting LLC-induced MPE. This specific effect was evidenced by significant reductions in effusion accumulation and the associated mortality and was observed with both preventive (beginning before MPE formation) and therapeutic (beginning after MPE establishment) bortezomib treatment. The favorable impact of bortezomib on MPE was associated with suppression of cardinal MPE-associated phenomena, such as inflammation, vascular hyperpermeability, and angiogenesis. In this regard, therapeutic bortezomib treatment had identical favorable results on MPE compared with preventive treatment, indicating that the drug specifically counteracts effusion formation. Conclusions: These studies indicate that proteasome inhibition tailored to block NF-κ B activation of lung adenocarcinoma specifically targets the effusion-inducing phenotype of this tumor. Although the drug has limited activity against advanced solid lung cancer, it may prove beneficial for patients with MPE.Keywords
This publication has 32 references indexed in Scilit:
- Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)Journal of Thoracic Oncology, 2009
- A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural EffusionJNCI: Journal of the National Cancer Institute, 2008
- Pleural drainage and pleurodesis: implementation of guidelines in four hospitalsEuropean Respiratory Journal, 2008
- Epithelial NF-κB activation promotes urethane-induced lung carcinogenesisProceedings of the National Academy of Sciences, 2007
- Use of bioluminescent imaging to investigate the role of nuclear factor-κΒ in experimental non-small cell lung cancer metastasisClinical & Experimental Metastasis, 2007
- Tumor Necrosis Factor-α Promotes Malignant Pleural EffusionCancer Research, 2007
- Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- NF-κB functions as a tumour promoter in inflammation-associated cancerNature, 2004
- BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in MiceJournal of Biological Chemistry, 2003
- The Hallmarks of CancerCell, 2000